EGFR and non-small cell lung carcinoma: In the context of the clinical study AURA, it was evaluated the clinical efficacy of osimertinib on a group of NSCLC patients experimenting disease progression after one or more treatments with first and second- generation EGFR TKIs, related to the development of Thr790Met mutation; median PFS was 11.1 months and median OS was 16.9 months [332].